BioPorto A/S

BioPorto A/S is an in vitro diagnostics company dedicated to developing and commercializing actionable biomarkers to improve patient management, primarily focusing on kidney health. Headquartered in Copenhagen, Denmark, with facilities also in Boston, MA, USA, the company's mission is to save lives and enhance the quality of life through early and accurate disease detection.

The company's core product portfolio centers on the Neutrophil Gelatinase-Associated Lipocalin (NGAL) biomarker, which aids in the risk assessment and diagnosis of Acute Kidney Injury (AKI). Key products include ProNephro AKI (NGAL), the first FDA 510(k) cleared AKI biomarker test for pediatric use (ages 3 months through 21 years) in the US, commercially available through a collaboration with Roche Diagnostics. BioPorto also offers The NGAL Test, which is CE-marked for in vitro diagnostic use in the EU and registered in several other countries, and available for Research Use Only in the United States. The company previously offered a range of antibodies and ELISA kits, but divested its antibody business in April 2026 to sharpen its focus on NGAL.

In recent developments, BioPorto appointed Carsten Buhl as its new Group CEO, effective September 1, 2025, with Peter Mørch Eriksen transitioning from the role. The company is actively pursuing an FDA application for adult use of ProNephro AKI, with submission anticipated in the first half of 2027. This strategic focus on NGAL is expected to drive significant revenue growth, with aspirations to reach DKK 150-200 million in revenue by 2028 and over DKK 700 million by 2029. BioPorto A/S is publicly traded on the Nasdaq Copenhagen stock exchange under the ticker BIOPOR.